Skip to main content
SpringerLink
Log in

The Interface between Rheumatology and Dermatology

Why Rheumaderm?

  • Chapter
Rheumaderm

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 455))

Abstract

Although the division of medicine into specialties according to different systems is convenient, it is also artificial: the different systems interact and many diseases overlap both in their pathological features as well as their clinical expression. Many examples of such interactions are seen in the connective tissue disorders, where rheumatological and dermatological manifestations may be prominent features. In some of them the skin rash may be a diagnostic marker (e.g., systemic lupus erythematosus, dermatomyositis). Joint involvement can also be found in “primary” skin disorders such as psoriasis; certain infections can produce both skin and joint manifestations including a number of fairly common viral disorders as well as Lyme borelliosis and the acquired immune deficiency syndrome (A.I.D.S.) The skin may also be the major target of toxicity from a number of drugs, particularly those that are used in the management of rheumatic disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yung RL, Richardson BC. Drug Induced Lupus. Rheum Dis Clin North Am. 20: 61–86. 1994.

    PubMed  CAS  Google Scholar 

  2. Price EJ, Venables PJ. Drug-induced lupus. Drug Saf. 12: 283–290. 1995

    Article  PubMed  CAS  Google Scholar 

  3. Gunnarson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sul-phasalazine-induced systemic lupus erythematosus. Br J Rheumatol. 36: 1089–1094. 1997.

    Article  Google Scholar 

  4. McGuiness M, Frye RA, Deng JS. Atenolol-induced lupus erythematosus. J Am Acad Dermatol. 37: 298–299. 1997.

    Article  PubMed  CAS  Google Scholar 

  5. Eyanson S, Greist MC, Brandt KD, Skinner B. Systemic lupus erythematosus: association with psoralen-ultraviolet A treatment of psoriasis. Arch Dermatol 115: 54–56. 1979.

    Article  PubMed  CAS  Google Scholar 

  6. McGrath H Jr., Scopelitis E, Nesbitt LT Jr. Subacute cutaneous lupus erythematosus during psoralen ultraviolet A therapy. Arthrit Rheum 33: 302–303. 1990.

    Article  Google Scholar 

  7. Kilbourne EM, Philen RM, Kamb ML, Falk H. Tryptophan produced by Showa Denko and epidemic eosi-nophilia-myalgia syndrome. J Rheumatol (Suppl). 46: 81–88. 1996.

    CAS  Google Scholar 

  8. Bigby M, Stern R. Cutaneous reactions to nonsteroidal anti-inflammatory drugs. A review. J Am Acad Dermatol. 12: 866–876. 1985.

    Article  CAS  Google Scholar 

  9. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 127: 839–842. 1991.

    CAS  Google Scholar 

  10. Wilkinson SM, Smith AG, Davis MJ, Mattey DL, Dawes PT. Suspected drug toxicity in rheumatoid arthritis — an evaluation. Br J Rheumatol 32: 798–803 (1993)

    Article  PubMed  CAS  Google Scholar 

  11. Roth DE, Spencer LV, Abrens EM. Cutaneous reactions to drugs used for rheumatologic disorders. Med Clin North Am. 73: 1275–1298. 1989.

    PubMed  CAS  Google Scholar 

  12. Broggini M, Baratelli E, Cappelli A, Crespi E, Filardi PG, Volonte S. Cutaneous side effects induced by D-penicillamine in the treatment of rheumatoid arthritis. Minerva Med 81: 197–201 1990.

    PubMed  CAS  Google Scholar 

  13. Skeith KJ, Russell AS. Adverse reactions to sulfasalazine. J Rheumatol 15: 529–530. 1988.

    PubMed  CAS  Google Scholar 

  14. Pullar T. Adverse effects of sulphasalazine. Adverse Drug React Toxicol Rev. 11: 93–l09. 1992.

    PubMed  CAS  Google Scholar 

  15. Koranda FC. Antimalarials. J Am Acad Dermatol. 4: 650–655. 1981.

    Article  PubMed  CAS  Google Scholar 

  16. Levy H. Chloroquine-induced pigmentation. Case reports. S. Afr Med J. 62: 735–737. 1982.

    CAS  Google Scholar 

  17. Veraldi S, Schianchi-Veraldi R, Scarabelli G. Pigmentation of the gums following hydroxycholoroquine therapy. Cutis. 49: 281–281. 1992.

    PubMed  CAS  Google Scholar 

  18. Abel EA. Diagnosis of drug-induced psoriasis. Semin Dermatol. 11: 269–274. 1992.

    PubMed  CAS  Google Scholar 

  19. Segal R, Caspi D, Tishler M, Fishel B, Yaron M. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum. 31: 1182–1185. 1988.

    Article  PubMed  CAS  Google Scholar 

  20. Combe B, Didry C, Gutierrez M, Anaya JM, Sany J. Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur J Med. 2: 153–156. 1993.

    PubMed  CAS  Google Scholar 

  21. Wilson DJ, Kay V, Charig M, Hughes DG, Creasy Ts. Skeletal hyperostosis and extraosseous calcification in patients receiving long-term etretinate (Tigason). Br J Dermatol 119: 597–607. 1988.

    Article  PubMed  CAS  Google Scholar 

  22. Van Dooren-Greebe RJ, Lemmens JA, De Boo T, Hangs NM, Kuljpers AL, Van de Kerkhof. Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 134: 71–76. 1996.

    Article  PubMed  Google Scholar 

  23. Campbell RR, Hawkins SJ, Maddison PJ. Reckless JP. Limited joint mobility in diabetes mellitus. Ann Rheum Dis. 44: 93–97. 1985.

    Article  PubMed  CAS  Google Scholar 

  24. Brik R, Berant M, Vardi P. The scleroderma-like syndrome of insulin-dependent diabetes mellitus. Diabetes Metab Rev. 7: 120–128. 1991.

    Article  PubMed  CAS  Google Scholar 

  25. Sculte L, Roberts MS, Zimmerman C, Ketler J, Simon LS. A quantitative assessment of limited joint mobility in patients with diabetes. Arthritis Rheum. 36: 1429–1443. 1993.

    Article  Google Scholar 

  26. Rosenbloom AL, Silverstein JH. Connective tissue and joint disease in diabetes mellitus. Endocrinol Metab Clin North Am. 25: 473–83. 1996.

    Article  PubMed  CAS  Google Scholar 

  27. Azizi E, Fisher BK. Cutaneous manifestations of familial Mediterranean fever. Arch Dermato. 112: 364–366. 1976.

    Article  CAS  Google Scholar 

  28. Majeed HA, Quabazard Z, Hijazi Z, Farwana S, Harshani F. The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study. QJ Med. 278: 607–616. 1990.

    Google Scholar 

  29. Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc. 70: 559–564. 1995.

    Article  PubMed  CAS  Google Scholar 

  30. Duffy J. Lyme Disease: a clinical review. Minn Med. 74: 21–26. 1991.

    PubMed  CAS  Google Scholar 

  31. Burgorfer W. Lyme borreliosis: ten years after discovery of the etiologic agent, Borrelia burgdorferi. Infection. 19: 257–262. 1991.

    Article  Google Scholar 

  32. Calabrese LH. Human immunodeficiency virus (HIV) infection and arthritis. Rheum Dis Clin North Am. 19: 477–488. 1993.

    PubMed  CAS  Google Scholar 

  33. Uthayamumar S, Nandwani R, Drinkwater T, Nayagam AT, Darley CR. The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol. 137: 595–598. 1997.

    Article  Google Scholar 

  34. Hughes GR, Khamashta MA. The Antiphospholipid Syndrome. J R Coll Physicians Lond. 28: 301–314. 1994.

    PubMed  CAS  Google Scholar 

  35. Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol. 36: 970–982. 1997.

    Article  PubMed  CAS  Google Scholar 

  36. Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients with Raynaud’s phenomenon: a six year follow up with emphasis on the predictive value of antinu-clear antibodies as detected by immunoblotting. Ann Rheum Dis. 47: 634–641. 1988.

    Article  PubMed  CAS  Google Scholar 

  37. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud’s phenomenon: a longterm prospective study. J Rheumatol. 22: 2226–2232. 1995.

    PubMed  CAS  Google Scholar 

  38. Bynum WF. The Great Imitator: Syphilis in Historical Perspective. Medicine Int. 24: 12. 1996.

    Google Scholar 

  39. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 27: 337–343. 1993.

    PubMed  CAS  Google Scholar 

  40. Carrington PR, Sanusi ID, Zahradka S, Winder PR. Enalapril-associated erythema and vasculitis. Cutis. 51: 121–123. 1993.

    PubMed  CAS  Google Scholar 

  41. Lanctot KL, Ghajar BM, Shear NH, Naranjo CA. Improving the diagnosis of hypersensitivity reactions associated with sulphonamides. J Clin Pharmacol. 34: 1228–1233. 1994.

    PubMed  CAS  Google Scholar 

  42. Hannedouche T, Fillastre JP. Penicillin-induced hypersensitivity vasculitides. J Antimicrob Chemother. 20: 3–5. 1987.

    Article  PubMed  CAS  Google Scholar 

  43. Stubbings J. Sheehan-Dare R, Walton S. Cutaneous vasculitis due to ciprofloxacin. Brit Med J. 305: 29. 1992.

    Article  PubMed  CAS  Google Scholar 

  44. Ribard P, Kahn MF. Rheumatological side effects of quinolones. Clin Rheumatol. 5: 175–191. 1991.

    CAS  Google Scholar 

  45. Kelly JR, Andolsek K. Tetracycline toxicity presenting as generalised vasculitis. South Med J. 71: 961–963. 1978.

    Article  PubMed  CAS  Google Scholar 

  46. Elkayam O, Yaron M, Caspi D. Minocycline induced arthritis assoicated with fever, livedo reticularis, and pANCA. Ann Rheum Dis. 55: 769–771. 1996.

    Article  PubMed  CAS  Google Scholar 

  47. Bjornberg A, Gisslen H. Thiazides: A cause of necrotising vasculitis? Lancet. 2: 982–983. 1965.

    Article  PubMed  CAS  Google Scholar 

  48. Cox NH, Hodkin P. Vasculitis due to metolazone. Postgrad Med J. 67: 860. 1991.

    Article  PubMed  CAS  Google Scholar 

  49. Lin RY. Unusual autoimmune manifestations in furosemide-associated hypersensitivity angiitis. NY State J Med. 88: 439–440. 1988.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, St. Luke’s Hospital, Guardamangia, Malta, USA

    Dr. Carmel Mallia MD FRCP(Edin) FRCP(Lond), Chairman

Authors
  1. Dr. Carmel Mallia MD FRCP(Edin) FRCP(Lond), Chairman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmel Mallia MD FRCP(Edin) FRCP(Lond), Chairman .

Editor information

Editors and Affiliations

  1. St. Luke’s Hospital, University of Malta Medical School, Malta, USA

    Carmel Mallia

  2. Jefferson Medical College, Thomas Jefferson Universit, Philadelphia, Pennsylvania, USA

    Jouni Uitto

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mallia, C. (1999). The Interface between Rheumatology and Dermatology. In: Mallia, C., Uitto, J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4857-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4857-7_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7203-5

  • Online ISBN: 978-1-4615-4857-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation